tbuckley/cabot-search huggingface dataset:
Precise and efficient silencing of mutant Kras<sup>G12D</sup> by CRISPR-CasRx controls pancreatic cancer progression
Authors: Wang Jiang, Hao Li, Xiyu Liu, Jianping Zhang, Wuhu Zhang, Tianjiao Li, Liang Liu, Xianjun Yu
Journal: Theranostics (2020)

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with few therapeutic targets and rare effective treatments. Over 90% of PDAC tumors bear a Kras mutation, and the single-site mutation G12D (Kras
1820P Taxane-related skin toxicity: Analysis of an in vivo and 3D in vitro model study of the impact of paclitaxel on skin
Authors: M. Perez-Leal, J.A. Perez Fidalgo, C. Sanz, J. Poveda, J. Milara, P. Martinez, A. Cervantes, J. Cortijo
Journal: Annals of Oncology (2020)
Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography
Authors: Boyu Meng, Margaret R. Folaron, Rendall R. Strawbridge, Negar Sadeghipour, Kimberley S. Samkoe, Kenneth Tichauer, Scott C. Davis
Journal: Theranostics (2020)

Immuno-oncological treatment strategies that target abnormal receptor profiles of tumors are an increasingly important feature of cancer therapy. Yet, assessing receptor availability (RA) and drug-target engagement, important determinants of therapeutic efficacy, is challenging with current imaging strategies, largely due to the complex nonspecific uptake behavior of imaging agents in tumors. Herein, we evaluate whether a quantitative noninvasive imaging approach designed to compensate for nonspecific uptake, MRI-coupled paired-agent fluorescence tomography (MRI-PAFT), is capable of rapidly assessing the availability of epidermal growth factor receptor (EGFR) in response to one dose of anti-EGFR antibody therapy in orthotopic brain tumor models. Methods: Mice bearing orthotopic brain tumor xenografts with relatively high EGFR expression (U251) (N=10) or undetectable human EGFR (9L) (N=9) were considered in this study. For each tumor type, mice were either treated with one dose of cetuximab, or remained untreated. All animals were scanned using MRI-PAFT, which commenced immediately after paired-agent administration, and values of RA were recovered using a model-based approach, which uses the entire dynamic sequence of agent uptake, as well as a simplified "snapshot" approach which requires uptake measurements at only two time points. Recovered values of RA were evaluated between groups and techniques. Hematoxylin & eosin (H&E) and immunohistochemical (IHC) staining was performed on tumor specimens from every animal to confirm tumor presence and EGFR status. Results: In animals bearing EGFR(+) tumors, a significant difference in RA values between treated and untreated animals was observed (RA = 0.24 ± 0.15 and 0.61 ± 0.18, respectively, p=0.027), with an area under the curve - receiver operating characteristic (AUC-ROC) value of 0.92. We did not observe a statistically significant difference in RA values between treated and untreated animals bearing EGFR(-) tumors (RA = 0.18 ± 0.19 and 0.27 ± 0.21, respectively; p = 0.89; AUC-ROC = 0.55), nor did we observe a difference between treated EGFR(+) tumors compared to treated and untreated EGFR(-) tumors. Notably, the snapshot paired-agent strategy quantified drug-receptor engagement within just 30 minutes of agent administration. Examination of the targeted agent alone showed no capacity to distinguish tumors either by treatment or receptor status, even 24h after agent administration. Conclusions: This study demonstrated that a noninvasive imaging strategy enables rapid quantification of receptor availability in response to therapy, a capability that could be leveraged in preclinical drug development, patient stratification, and treatment monitoring.
1063P Profiling of peripheral T cell receptor beta chain repertoire in non-small cell lung cancer (NSCLC) patients treated with anti-PD1
Authors: N. Dong, A. Panizza, A. Moreno, S. Gallach, F. Zhang, M. Meri Abad, F.D.A. Aparisi Aparisi, A. Blasco Cordellat, I. Shaheen, M. Ferrero Gimeno, S. Calabuig-Fariñas, E. Jantus Lewintre, C.J.C. Camps Herrero
Journal: Annals of Oncology (2020)
202P Role of micrometastases in sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients
Authors: J. Ponce, S. Delgado, H. Ballester, T. Martín, G. Peiró, Y.G. Montoyo-Pujol, M. Garcia-Escolano, F. Aranda, M. Niveiro, M. Reche, A. Rodriguez-Lescure, I. Lozano, B. Massuti Sureda
Journal: Annals of Oncology (2020)
Association of Prenatal Alcohol Exposure With Psychological, Behavioral, and Neurodevelopmental Outcomes in Children From the Adolescent Brain Cognitive Development Study
Authors: Briana Lees, Louise Mewton, Joanna Jacobus, Emilio A. Valadez, Lexine A. Stapinski, Maree Teesson, Susan F. Tapert, Lindsay M. Squeglia
Journal: American Journal of Psychiatry (2020)

Data on the neurodevelopmental and associated behavioral effects of light to moderate in utero alcohol exposure are limited. This retrospective investigation tested for associations between reported maternal prenatal alcohol use and psychological, behavioral, and neurodevelopmental outcomes in substance-naive youths.Participants were 9,719 youths (ages 9.0 to 10.9 years) from the Adolescent Brain Cognitive Development Study. Based on parental reports, 2,518 (25.9%) had been exposed to alcohol in utero. Generalized additive mixed models and multilevel cross-sectional and longitudinal mediation models were used to test whether prenatal alcohol exposure was associated with psychological, behavioral, and cognitive outcomes, and whether differences in brain structure and resting-state functional connectivity partially explained these associations at baseline and 1-year follow-up, after controlling for possible confounding factors.Prenatal alcohol exposure of any severity was associated with greater psychopathology, attention deficits, and impulsiveness, with some effects showing a dose-dependent response. Children with prenatal alcohol exposure, compared with those without, displayed greater cerebral and regional volume and greater regional surface area. Resting-state functional connectivity was largely unaltered in children with in utero exposure. Some of the psychological and behavioral outcomes at baseline and at the 1-year follow-up were partially explained by differences in brain structure among youths who had been exposed to alcohol in utero.Any alcohol use during pregnancy is associated with subtle yet significant psychological and behavioral effects in children. Women should continue to be advised to abstain from alcohol consumption from conception throughout pregnancy.
Imaging‐Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and Diagnostic Performance
Authors: Saira Akbarali, Jugnoo S. Rahi, Andrew D. Dick, Kiren Parkash, Katie Etherton, Clive Edelsten, Xiaoxuan Liu, Ameenat L. Solebo
Journal: Arthritis & Rheumatology (2020)

Children with juvenile idiopathic arthritis (JIA) need regular examinations for uveitis to avoid visual morbidity from the most common extraarticular manifestation of disease. This study was undertaken to investigate the feasibility, acceptability, and performance of optical coherence tomography (OCT) imaging-based diagnosis of uveitis. This observational cross-sectional study included children with and those without uveitis. The children underwent routine clinical examinations and anterior segment OCT scanning of intraocular inflammatory cells. Acceptability of image acquisition was assessed using a visual analog scale and length of time needed to acquire images. Interobserver and intraobserver variability of manual counting of acquired images (Bland-Altman limits of agreement), correlation between imaging and routine assessment, and sensitivity and specificity of anterior segment OCT detection of active inflammation were assessed. Of the 26 children ages 3-15 years (median age 8 years) who underwent imaging, 12 had active inflammation. All patients rated the acceptability of image acquisition as at least 8.5 on a scale of 0-10. Time taken to acquire images ranged from 1.5 minutes to 22 minutes (median time 8 minutes). There was good positive correlation between clinical assessment and image-based cell quantification (R2 = 0.63, P = 0.002). Sensitivity of anterior segment OCT manual image cell count for diagnosis of active inflammation was 92% (95% confidence interval [95% CI] 62-99%), specificity was 86% (95% CI 58-98%), and negative predictive value (ruling out uveitis) was 92% (95% CI 65-99%). Non-contact, high-resolution imaging for JIA uveitis surveillance is feasible, acceptable to patients, and holds the promise of transforming pediatric practice. Further work is needed to determine the analytic and clinical validity of anterior segment OCT quantification of active inflammation, and the clinical utility and cost-effectiveness of imaging-based disease monitoring.
1456P Retrospective comparative analysis of S-1 and oxaliplatin or cisplatin as first-line therapy in metastatic gastric cancer in a European population
Authors: A. Koumarianou, A. Ntavatzikos, C. Vallilas, K. Kampoli, Z. Kokosaiou, M.V. Karamouzis
Journal: Annals of Oncology (2020)
811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Authors: S. Banerjee, K.N. Moore, N. Colombo, G. Scambia, B-G. Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, A. Oza, A. González Martín, C. Aghajanian, W. Bradley, E. Holmes, E.S. Lowe, P. DiSilvestro
Journal: Annals of Oncology (2020)
1142P Treatment of metastatic uveal melanoma (mUM) through genomic profiling
Authors: S. Leyvraz, M. Schütte, T. Kessler, T. Risch, G. Dörpholz, S. Ochsenreither, D.T. Rieke, V. Amstislavskiy, C. Wierling, F. Klauschen, C.A. Peuker, M. Lamping, I. Jelas, S. Burock, R. Schäfer, B. Lange, C. Ulrich, A. Joussen, U. Keilholz, M-L. Yaspo
Journal: Annals of Oncology (2020)
1996P Clinical significance of ephrin receptor (EPH)-B1, -B2, -B4 and -B6 expression in thymic epithelial tumours
Authors: C. Masaoutis, P. Sarantis, N. Tsoukalas, S. Kokkali-Zervos, P. Alexandrou, D. Rontogianni, S. Theocharis
Journal: Annals of Oncology (2020)
1405P Survival of patients with non-small cell lung cancer and exon 20 insertion mutation from the Czech Republic
Authors: J. Skrickova, M. Pesek, P. Opalka, L. Koubkova, M. Zemanová, M. Hrnciarik, A. Benejova, J. Blazek, M. Svaton, J. Krejci, H. Coupkova, D. Dolezal, T. Vlasek, T. Tuzova, L. Holubec, P. Mahadevia, K. Sandstrom, P. Kunovszki, M. Bratova
Journal: Annals of Oncology (2020)
1113P Mortality prediction in real world advanced melanoma patients treated by anti-PD1 within MelBase, a French multicentric prospective cohort
Authors: B. Oriano, S. Dalle, L. Mortier, C. Dutriaux, O. Dereure, M-T. Leccia, S. Dalac, D. Legoupil, J. De Quatrebarbes, H. Montaudié, J.P. Arnault, F. Brunet Possenti, P. Saiag, E. Maubec, T. Lesimple, F. Aubin, F. Granel-Brocard, B. Dréno, R. Porcher, C. Lebbé
Journal: Annals of Oncology (2020)
1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
Authors: S-E. Al-Batran, S. Lorenzen, P.C. Thuss-Patience, M. Schenk, E. Goekkurt, R.D. Hofheinz, A. Kretzschmar, V. Heuer, C. Bolling, G.M. Haag, S. Angermeier, L. Fischer von Weikersthal, W.O. Bechstein, A. Wicki, A. Siebenhüner, L. Waberer, N. Irahara, C. Pauligk, T.O. Götze, N. Homann
Journal: Annals of Oncology (2020)
Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study
Authors: Bernadette Schurink, Eva Roos, Teodora Radonic, Ellis Barbe, Catherine S C Bouman, Hans H de Boer, Godelieve J de Bree, Esther B Bulle, Eleonora M Aronica, Sandrine Florquin, Judith Fronczek, Leo M A Heunks, Menno D de Jong, Lihui Guo, Romy du Long, Rene Lutter, Pam C G Molenaar, E Andra Neefjes-Borst, Hans W M Niessen, Carel J M van Noesel, Joris J T H Roelofs, Eric J Snijder, Eline C Soer, Joanne Verheij, Alexander P J Vlaar, Wim Vos, Nicole N van der Wel, Allard C van der Wal, Paul van der Valk, Marianna Bugiani
Journal: The Lancet Microbe (2020)
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis
Authors: Holger J Schünemann, Matthew Ventresca, Mark Crowther, Matthias Briel, Qi Zhou, Simon Noble, Fergus Macbeth, Gareth Griffiths, David Garcia, Gary H Lyman, Marcello Di Nisio, Alfonso Iorio, Lawrence Mbuagbaw, Ignacio Neumann, Nick van Es, Melissa Brouwers, Gordon Guyatt, Michael B Streiff, Maura Marcucci, Tejan Baldeh, Ivan D Florez, Ozlem Gurunlu Alma, Ziad Solh, Patrick M Bossuyt, Lara A Kahale, Walter Ageno, George Bozas, Harry R Büller, Bernard Lebeau, Ramon Lecumberri, Charles Loprinzi, Robert McBane, Kostandinos Sideras, Anthony Maraveyas, Uwe Pelzer, James Perry, Clara Klerk, Giancarlo Agnelli, Elie A Akl
Journal: The Lancet Haematology (2020)
Autoantibody Landscape in Patients with Advanced Prostate Cancer
Authors: William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga Carretero, Ivan Perez Garcilazo, Meng Zhang, Shuang G. Zhao, Martin Sjöström, David A. Quigley, Jonathan Chou, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Primo Lara, Kim N. Chi, Robert E. Reiter, Joshi J. Alumkal, Alan Ashworth, Rahul Aggarwal, Eric J. Small, Patrick S. Daugherty, Antoni Ribas, David Y. Oh, John C. Shon, Felix Y. Feng
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic castration-resistant prostate cancer (mCRPC). Experimental Design: Serum antibody epitope repertoire analysis (SERA) was performed on patient serum to identify tumor-specific neoepitopes. Somatic mutation–specific neoepitopes were investigated by associating serum epitope enrichment scores with whole-genome sequencing results from paired solid tumor metastasis biopsies and germline blood samples. A protein-based immunome-wide association study (PIWAS) was performed to identify significantly enriched epitopes, and candidate serum antibodies enriched in select patients were validated by ELISA profiling. A distinct cohort of patients with melanoma was evaluated to validate the top cancer-specific epitopes. Results: SERA was performed on 1,229 serum samples obtained from 72 men with mCRPC and 1,157 healthy control patients. Twenty-nine of 6,636 somatic mutations (0.44%) were associated with an antibody response specific to the mutated peptide. PIWAS analyses identified motifs in 11 proteins, including NY-ESO-1 and HERVK-113, as immunogenic in mCRPC, and ELISA confirmed serum antibody enrichment in candidate patients. Confirmatory PIWAS, Identifying Motifs Using Next-generation sequencing Experiments (IMUNE), and ELISA analyses performed on serum samples from 106 patients with melanoma similarly revealed enriched cancer-specific antibody responses to NY-ESO-1. Conclusions: We present the first large-scale profiling of autoantibodies in advanced prostate cancer, utilizing a new antibody profiling approach to reveal novel cancer-specific antigens and epitopes. Our study recovers antigens of known importance and identifies novel tumor-specific epitopes of translational interest.
Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice
Authors: Qian Lin, Zhifeng Huang, Genxiang Cai, Xia Fan, Xiaoqing Yan, Zhengshuai Liu, Zehua Zhao, Jingya Li, Jia Li, Hongxue Shi, Maiying Kong, Ming‐Hua Zheng, Daniel J. Conklin, Paul N. Epstein, Kupper A. Wintergerst, Moosa Mohammadi, Lu Cai, Xiaokun Li, Yu Li, Yi Tan
Journal: Hepatology (2020)

Background and Aims Fibroblast growth factor (FGF) 1 demonstrated protection against nonalcoholic fatty liver disease (NAFLD) in type 2 diabetic and obese mice by an uncertain mechanism. This study investigated the therapeutic activity and mechanism of a nonmitogenic FGF1 variant carrying 3 substitutions of heparin‐binding sites (FGF1 △HBS ) against NAFLD. Approach and Results FGF1 △HBS administration was effective in 9‐month‐old diabetic mice carrying a homozygous mutation in the leptin receptor gene ( db/db ) with NAFLD; liver weight, lipid deposition, and inflammation declined and liver injury decreased. FGF1 △HBS reduced oxidative stress by stimulating nuclear translocation of nuclear erythroid 2 p45‐related factor 2 (Nrf2) and elevation of antioxidant protein expression. FGF1 △HBS also inhibited activity and/or expression of lipogenic genes, coincident with phosphorylation of adenosine monophosphate–activated protein kinase (AMPK) and its substrates. Mechanistic studies on palmitate exposed hepatic cells demonstrated that NAFLD‐like oxidative damage and lipid accumulation could be reversed by FGF1 △HBS . In palmitate‐treated hepatic cells, small interfering RNA (siRNA) knockdown of Nrf2 abolished only FGF1 △HBS antioxidative actions but not improvement of lipid metabolism. In contrast, AMPK inhibition by pharmacological agent or siRNA abolished FGF1 △HBS benefits on both oxidative stress and lipid metabolism that were FGF receptor (FGFR) 4 dependent. Further support of these in vitro findings is that liver‐specific AMPK knockout abolished therapeutic effects of FGF1 △HBS against high‐fat/high‐sucrose diet–induced hepatic steatosis. Moreover, FGF1 △HBS improved high‐fat/high‐cholesterol diet–induced steatohepatitis and fibrosis in apolipoprotein E knockout mice. Conclusions These findings indicate that FGF1 △HBS is effective for preventing and reversing liver steatosis and steatohepatitis and acts by activation of AMPK through hepatocyte FGFR4.
1984P Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in patients undergoing neo-adjuvant chemotherapy
Authors: B.L. Rapoport, J. Galon, S. Nayler, A. Fugon, M. Martel, B. Mlecnik, C.A. Benn, F. Moosa, R. Anderson
Journal: Annals of Oncology (2020)
LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden
Authors: P. Van Mol, A. Franken, C. Dooms, J. Yserbyt, D. Testelmans, P. Meersseman, G. Hermans, J. Wauters, J. Gunst, K. Nackaerts, J. Vansteenkiste, A. Garg, D. Lambrechts, E. Wauters
Journal: Annals of Oncology (2020)
Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort‘
Authors: Meredith J Ventura, Emmanuel Guajardo, Eva H Clark, Kalpana Bhairavarasu, Riyad Y Kherallah, Andrew R DiNardo, Xunyan Ye, Pedro A Piedra, Robert L Atmar, Sandeep K Agarwal
Journal: Annals of the Rheumatic Diseases (2020)

We read with great interest the article by Pouletty et al reporting 16 paediatric patients presenting with Kawa-COVID-19, an inflammatory syndrome similar to Kawasaki disease (KD) associated with SARS-CoV-2 infection.1 All 16 patients met criteria for complete or incomplete KD. Severe cases in children involving systemic inflammation and multiorgan involvement related to COVID-19 are increasingly being reported. These cases, named multisystem inflammatory syndrome in children (MIS-C) in the USA and pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 in the UK, share features of both KD and macrophage activation syndrome.2–6 In contrast to children, few adults with KD-like cases have been reported.7 8 Herein, we describe an adult who presented with KD-like illness similar to children in the Kawa-COVID-19 cohort 4 weeks following a documented SARS-CoV-2 infection.

A 38-year-old Hispanic woman developed fever, dyspnoea, cough, anosmia, myalgias and polyarthralgias of the hands, wrists, elbows and knees 4 weeks prior to admission. At that time, nasopharyngeal SARS-CoV-2 PCR was positive. Her symptoms completely resolved within 2 weeks. Five days prior to …
Nosocomial measles cluster in Denmark following an imported case, December 2008-January 2009
Authors: C Groth, B  E Böttiger, A Plesner, A  H Christiansen, S Glismann, B Hogh
Journal: Eurosurveillance (2009)

A cluster of six confirmed cases with identical measles virus genotype was reported in Denmark between December 2008 and January 2009. The findings highlight the importance of vaccination before travelling and adherence to the routine vaccination schedule.
836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Authors: E.P. Hamilton, M.A. Barve, A.W. Tolcher, J. Buscema, K.P. Papadopoulos, C. Zarwan, C.K. Anderson, D. Doroshow, D. Wang, D. Huebner, V.M. Jansen, D. Jarlenski, R. Mosher, J. Kaufman, K.N. Moore, D.L. Richardson
Journal: Annals of Oncology (2020)
348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Authors: D. Eiger, C. Maurer, M. Brandao, P.G. Aftimos, K. Punie, D. Taylor, T. Van den Mooter, R. Poncin, J-L. Canon, F. Duhoux, V. Casert, F. Clatot, C. Velghe, L. Craciun, M. Paesmans, E. de Azambuja, M. Ignatiadis, D. Larsimont, M. Piccart, L. Buisseret
Journal: Annals of Oncology (2020)
1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC
Authors: J. Mazieres, A. Rittmeyer, S.M. Gadgeel, T. Hida, D. Gandara, D. Cortinovis, F. Barlesi, W. Yu, C. Matheny, M. Ballinger, K. Park
Journal: Annals of Oncology (2020)
Electromagnetically Transparent Graphene Respiratory Sensors for Multimodal Small Animal Imaging
Authors: Martin E. P. Tweedie, Veerle Kersemans, Stuart Gilchrist, Sean Smart, Jamie H. Warner
Journal: Advanced Healthcare Materials (2020)

Abstract Magnetic resonance imaging (MRI) and computed tomography (CT) imaging with X‐rays are crucial diagnostic techniques in medicine, especially in oncology for evaluating the response to treatment. Body movement causes image blurring and synchronized gating to the respiratory and cardiac cycles is required. Degradation of MRI and CT imaging by the presence of metal in electronic respiratory sensors has limited their use, with a preference for pressure balloons for detecting respiration, but these are cumbersome and insensitive. Here, graphene's role is studied as an electromagnetically transparent electrode in a piezoelectric graphene respiratory sensor (GRS) device designed specifically for dual gated MRI and CT imaging of small animals. The GRS is integrated into a 3D‐printed cradle with all‐carbon‐based device life support (heating pad) and monitoring of small animals (electrocardiogram), enabling both heartbeat and respiration detection, significant improvements to throughput and reproducibility, and reduced animal suffering. This shows graphene's potential for a wide range of electromagnetic transparent electronics for medical imaging and diagnostics, beyond conventional metal electrodes.
439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
Authors: D-Y. Oh, T. Arkenau, K-W. Lee, M. Alsina, F.M. Marti, I.J. Chung, W. Saif, D. Wang, P. O'Dwyer, I. Chau, M-A. Lee, E. Chong, J. Hilger-Rolfe, G. Cole, S.Y. Kim
Journal: Annals of Oncology (2020)